All articles by Manish Kumar
Manish Kumar
Palleon partners with Henlius to develop autoimmune disease treatment
The collaboration and licence agreement aims to treat autoimmune diseases, including lupus nephritis, using E-602 with Henlius’ Hanlikang in combination therapy
Merck’s doravirine/islatravir combo yields positive results in Phase 3 HIV-1 trials
The doravirine/islatravir combination met primary efficacy and safety objectives in two Phase 3 trials involving adults with virologically suppressed HIV-1
Assembly announces $30.1m equity investment and accelerated funding from Gilead to advance clinical development programs
Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026
Abilita and Orion join forces to develop next-gen cancer therapies
Both companies will develop antibody therapeutics for oncology and pain, using Abilita’s EMP platform to target challenging multi-span membrane proteins
Mesoblast’s Ryoncil gets FDA nod as first MSC therapy for SR-aGvHD
Ryoncil is the only FDA-approved allogeneic MSC therapy for any indication and currently the sole treatment for steroid-refractory acute graft-versus-host disease in the US
Johnson & Johnson seeks EMA approval for new indication of IMBRUVICA in untreated MCL
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months fixed-duration ibrutinib therapy
Gilead, Terray forge small molecule drug development partnership
Terray will use its tNova platform to develop small molecule compounds for Gilead, which may exclusively license and commercialise them upon exercise of its option
Teva and Sanofi’s duvakitug meets primary endpoints in Phase 2b IBD trial
Both companies now plan Phase 3 development of duvakitug for UC and CD, pending regulatory discussions, as part of their co-development and commercialisation collaboration
Aflibercept 8 mg met primary endpoint in phase III study and demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Approximately 90% of aflibercept 8 mg patients were extended to every 8-week dosing and maintained their interval through 36 weeks
Johnson & Johnson submits sBLA for Simponi in paediatric UC treatment
Simponi is an anti-TNF biologic that blocks the TNF-alpha protein and is already approved for treating adults with moderately to severely active ulcerative colitis